NIH STRATEGIC PLAN FOR AIDS RESEARCH RELATED TO RACIAL AND ETHNIC MINORITIES by Office of AIDS, Research
 NIH STRATEGIC PLAN FOR AIDS RESEARCH 
 RELATED TO RACIAL AND ETHNIC MINORITIES 
 
 
THE NIH AIDS RESEARCH PROGRAM 
 
The Role of the Institutes 
Each NIH component supports HIV/AIDS-related research activities, consistent with its 
individual mission.  The ICs whose research programs are most heavily concerned with 
HIV, AIDS, and their sequelae are the National Institute of Allergy and Infectious Diseases 
(NIAID), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), 
the National Institute of Mental Health (NIMH), the National Center for Research Resources 
(NCRR), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute 
of Child Health and Human Development (NICHD).  The Warren Grant Magnuson Clinical 
Center provides the infrastructure for intramural clinical studies sponsored by the ICs. 
 
The Role of the Office of AIDS Research 
OAR was established in 1988 by the Director of NIH and the Department of Health and 
Human Services (DHHS) Assistant Secretary of Health to coordinate the AIDS research 
effort across NIH and serve as a focal point for AIDS policy and budget development.  The 
NIH Revitalization Act of 1993 (Public Law 103-43) gave broad new authorities to the 
office.  OAR is responsible for the annual comprehensive planning and budgeting process 
for all NIH AIDS research and for preparation of a Presidential bypass budget.  The law also 
requires OAR to evaluate the AIDS activities of each of the ICs, as well as provide for the 
periodic reevaluation of such activities.  OAR maintains a discretionary fund, and the 
appropriations committees have provided OAR with transfer authority permitting it to move 
up to 3 percent of AIDS research funds among Institutes.  The OAR monitors and fosters 
plans for NIH involvement in international AIDS research activities. 
 
OAR has established and supported the efforts of five trans-NIH Coordinating Committees 
in the following areas: Natural History and Epidemiology, Etiology and Pathogenesis, 
Therapeutics, Vaccines, and Behavioral and Social Science.  The Committees represent 
those Institutes with the most significant research portfolios in these areas.  The Committees 
foster collaboration and coordination and assist in the development of the NIH Plan and 
budget for AIDS research.  In addition, OAR established the Ad Hoc Minority Working 
Group in 1999.  Composed of NIH staff and non-NIH scientists and experts, this group 
advises the OAR Director on needed research and research-related efforts specifically 
targeted to these populations. 
 
OAR also established the Global AIDS Research Strategy Group to bring together all of 
Institutes and Centers of the NIH with international AIDS research portfolios, the Centers 
for Disease Control and Prevention, and the U.S. Agency for International Development, to 
facilitate international research efforts.  
 
To carry out its activities, OAR depends upon the expert advice of several committees.  
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Each of these committees includes AIDS community representatives.  The OAR Advisory 
Council (OARAC) is composed of non-Government experts from a broad array of 
disciplines, as well as AIDS community representatives.  OARAC reviews the annual Plan 
and discretionary fund disbursements.  A list of current OARAC members is included as 
Appendix A.  OAR also has established the Prevention Science Working Group and the 
Therapeutics Research Working Group to provide advice in these critical scientific areas.  
 
OAR directly supports several programs and initiatives.  These include the Intramural AIDS 
Targeted Antiviral Program (IATAP) and the NIH AIDS Research Loan Repayment 
Program (LRP).  In addition, OAR recognizes the critical need to ensure that research results 
are translated into effective prevention programs and into clinical practice.  To accomplish 
this goal, OAR supports a number of activities to promote the distribution of research 
information to researchers, physicians, institutions, and communities. 
 
LEGISLATIVE MANDATE 
 
The Revitalization Act provided that the Director of the OAR shall “plan, coordinate and 
evaluate research and other activities conducted or supported” by NIH.  The OAR Director 
“shall act as the primary Federal official with responsibility for overseeing all AIDS 
research conducted or supported by the National Institutes of Health” and shall   
 
· “establish a comprehensive plan for the conduct and support of all AIDS 
activities of the agencies of the National Institutes of Health...;  
· ensure that the Plan establishes priorities among the AIDS activities that such 
agencies are authorized to carry out;  
· ensure that the Plan establishes objectives regarding such activities...;  
· ensure that all amounts appropriated for such activities are expended in 
accordance with the Plan;  
· review the Plan not less than annually and revise as appropriate...; and  
· ensure that the Plan serves as a broad, binding statement of policies regarding 
AIDS activities of the agencies, but does not remove the responsibility of the 
heads of the agencies for the approval of specific programs or projects, or for 
other details of the daily administration of such activities, in accordance with 
the Plan.”   
 
The law further mandates that the Plan provide for “basic research; ...applied research; 
research that is conducted by the agencies; ...research that is supported by the agencies; 
proposals developed pursuant to solicitations by the agencies and for proposals developed 
independently of such solicitations; and ...behavioral and social sciences research.” 
 
The law also provides that the OAR Director develop the NIH AIDS budget for each fiscal 
year based upon “budget estimates...for carrying out the Plan for the fiscal year,” including a 
budget to be sent directly to the President and the Congress. 
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OVERVIEW OF THE PLAN 
 
The Planning Process 
OAR has established a unique and effective model for developing a consensus on scientific 
priorities for the annual comprehensive NIH Plan for HIV-Related Research.  To develop 
the FY 2003 Plan, OAR sponsored a series of Planning Workshops to seek the input of 
non-NIH experts, including scientists from academia, foundations, and industry, and 
community representatives.  These experts participated with NIH scientific and program 
staff in Planning Groups for Natural History and Epidemiology; Etiology and Pathogenesis; 
Therapeutics; Vaccines; Behavioral and Social Science; Microbicides; HIV Prevention 
Research; Racial and Ethnic Minorities; Women and Girls and HIV/AIDS Research and 
International Research Priorities.  A list of participants in the Planning Group for Research 
Related to Racial and Ethnic Minorities is found in Appendix B.  Participants in each 
Planning Group were asked to review and revise the objectives and strategies of the draft 
Plan, based on the state of the science, and to identify a set of priorities for their area.  All 
groups were asked to address needs in the areas of information dissemination, training, 
infrastructure and capacity building related to their area.  The resulting draft Plan was then 
provided to each Institute and Center Director and AIDS Coordinator for recommendations 
and comments.  Finally, the Plan was reviewed by the Office of AIDS Research Advisory 
Council. 
 
OAR continues to reassess the planning process and make refinements in order to better 
capture the broadest range of expertise and community participation and to facilitate the 
identification of specific scientific priorities.  This year, new sections have been added to the 
Plan, focusing on Microbicides; HIV Prevention Research; and Women and Girls and 
HIV/AIDS Research. 
 
Structure of the Plan 
The Plan is divided into six Scientific Areas of Emphasis and six Areas of Special 
Emphasis.  Scientific Areas of Emphasis are Natural History and Epidemiology; Etiology 
and Pathogenesis; Therapeutics; Vaccines; Behavioral and Social Science; and 
Microbicides. Areas of Special Emphasis, which cross-cut all of the scientific areas, are HIV 
Prevention Research; Racial and Ethnic Minorities; Women and Girls and HIV/AIDS 
Research; International Research; Training, Infrastructure, and Capacity Building; and 
Information Dissemination. 
 
Scientific Issues and Priorities 
This section provides a scientific overview and specific priorities identified by the planning 
groups for each area.  These priorities narrowly define a few high-priority areas deemed 
most worthy of new or expanded funding, based on the current scientific knowledge, 
opportunities, and gaps.  They will be used to guide the development of the FY 2003 AIDS 
budget and to adjust the FY 2002 AIDS budget as needed. It is expected that these priorities 
will change from year to year, and thus expenditures in these areas will not be tracked over 
time. 
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Objectives and Strategies 
 
Objectives consist of a comprehensive list, in priority order, of the scientific questions to be 
addressed for each Scientific Area of Emphasis or Area of Special Interest. Under each 
Objective is a set of Strategies that provide examples of avenues and approaches that may be 
pursued. 
 
Uses of the Plan 
 
The Plan serves several purposes: 
· As the framework for developing the NIH AIDS budget. 
· For determining the use of NIH AIDS-designated dollars and for tracking and 
monitoring those expenditures. The Plan thus defines those research areas for which 
AIDS-designated funds may be allocated. 
· As a document that provides information to the public, the scientific community, 
Congress, and the AIDS-affected communities about the NIH AIDS research agenda. 
OAR distributes the annual comprehensive Plan to a wide audience, and it appears 
on the OAR Web site: http://www.nih.gov/od/oar/. 
 
STRATEGIC PLAN for AIDS RESEARCH  
RELATED to RACIAL and ETHNIC MINORITIES  
 
Scientific Issues: 
 
Significant gains have been made in the treatment of HIV infection, as well as in the 
elucidation of the complex mechanisms involved in the pathogenesis and pathophysiology 
of HIV infection.  Despite these gains, for over two decades, HIV infection has continued an 
inexorable march across racial and ethnic minority communities in the United States.  The 
increased number of treatment options, as well as the expanding number of clinical trials, 
has not significantly altered the course of HIV infection or transmission in these 
communities.  Racial and ethnic minorities continue to dominate new AIDS cases, as well as 
new HIV infections.  Many urban centers within the United States reflect HIV 
seroprevalence rates among racial and ethnic minorities that mimic those in the developing 
world. 
 
The interplay of cultural, economic, political, individual, and societal factors in general, 
especially within racial and ethnic minority communities, requires comprehensive and 
innovative interventions.  These interventions must include greater emphasis upon the 
training of minority scientists, as well as a long-term commitment to the production of 
skilled independent investigators.  The demographics of the epidemic, in stark contrast to the 
demographics of both extramural and intramural NIH investigators, reveal a widening divide 
between those infected and those conducting research upon the infected. 
 
However, race and ethnicity alone are insufficient to bridge the gap between the scientific 
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community and the communities most affected by HIV infection.  Within these 
communities, the main routes of HIV infection—unprotected sexual intercourse and 
substance abuse—are inextricably linked to a range of underlying community and societal 
factors, as well as community norms and culture.  Cultural competency, or the ability to see 
the world through the lens of a particular culture, not just cultural awareness, is a critical 
skill in understanding the context of the epidemic in racial and ethnic minority communities. 
 In addition to understanding the cultural context of HIV infection, these skills can result in 
designing clinical research that will produce outcomes that have relevance for these 
communities.  Focus groups have repeatedly demonstrated that research conducted with 
communities, rather than “for” or “on” communities is the only research that will be 
acceptable. 
 
Participation of racial and ethnic minority communities in clinical research can only serve to 
broaden scientific knowledge about HIV infection.  This would include identifying the 
impact, or lack thereof, of specific racial factors upon HIV pathogenesis, transmission, 
susceptibility, disease progression, and disease manifestation.  The high rates of other co-
morbid diseases in racial and ethnic minority communities, such as hepatitis C, also provide 
additional opportunities to determine the effect of these disease states upon not only HIV 
infection, but also upon treatment options for HIV infections, or the sequelae of treatment, 
such as metabolic abnormalities.  To achieve this objective, recruitment and retention 
strategies for clinical studies must be appropriate for the target population. Partnerships 
between NIH-funded research institutions and institutions within the community, including 
community-based organizations, present an opportunity for unique collaborations and 
greater community participation.  Through these partnerships the community and NIH can 
benefit from an exchange of ideas from research design to dissemination of research results. 
 
Regardless of clinical study type or design, the infrastructure within racial and ethnic 
minority communities is variable and may not sustain interventions tested in a community 
and found to be effective.  Recent revisions of the Declaration of Helsinki and National 
Bioethics Advisory Commission Ethical Guidelines remind us that research must leave a 
community “better off” than before the intervention was conducted. Research activities 
within racial and ethnic communities, as with any community, must recognize the value of 
the individuals and their unique contribution to their community and the wider society.  
Interventions that are effective, but not sustainable, represent a zero sum gain for the 
participating communities. 
 
Under-representation of racial and ethnic minorities in clinical research, as well as in the 
scientific community that conducts that research, is the product of a complex interplay of a 
number of factors.  With these factors ranging from racism and homophobia to mistrust and 
ignorance, the need for a new and innovative approach for increased minority representation 
across both the subject and investigator populations is clear.  A detailed and objective 
interdisciplinary review of the successes and failures of the NIH research and training 
programs in racial and ethnic minority communities, with action steps linked to quantifiable 
outcomes, is essential. 
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Priority for Future Research: 
· Invest and expand funding in research infrastructure at minority institutions to 
increase capacity to support HIV/AIDS research. 
 
Creative strategies to increase the numbers of racial and ethnic minorities who participate in 
clinical research and behavioral intervention studies, without a parallel effort to increase the 
number of skilled, independent minority investigators, will change little in the ongoing 
health disparity in HIV infection.  Community mistrust, only heightened by the consistent 
and ongoing paucity of minority investigators visible to the community, will continue to be a 
significant challenge.  Minority investigators at all institutions face challenges; however, 
those at minority institutions face significant challenges, due in part to the unique missions 
and environments at these institutions. Ensuring adequate resources for partnership 
development between minority-level and established university-level and federal research 
institutions is key.  Opportunities for faculty development, including the creation and 
support of partnerships between researchers at these institutions, would help foster 
collaboration.  As minority investigators are developed and stimulated, the creation and 
funding of innovative pilot sabbatical and fellowship programs to ensure protected research 
time is necessary.  Similarly, the identification and funding of senior visiting investigators 
for the purpose of enhancing the research capacity of minority investigators and institutions 
could serve as an additional catalyst at minority-predominant and minority-serving 
institutions.  Finally, the development and funding of HIV/AIDS research networks in these 
same institutions may assist in the development of the critical mass needed to produce 
productive senior investigators. 
 
Priority for Future Research: 
· Increase the number of funded minority investigators for greater efficacy in 
HIV research. 
 
In conjunction with infrastructure development, there are specific interventions necessary to 
expand the pool of minority investigators in HIV research.  The development and expansion 
of short- and long-term local and national mentoring programs among racial and ethnic 
minorities is essential.  There has been a consistent decline in the numbers of minorities 
selecting careers in the health sciences. To reverse such trends, there is a critical need to 
identify and develop strategies to recruit trainees and mentors at all levels, while providing 
economic and in-kind support.  Innovative grant mechanisms and training workshops that 
support the transition from trainee to independent investigator are also needed.  
Enhancement and expansion of academic training programs that provide the theoretical as 
well as practical framework for the conduct of clinical and basic research are especially 
needed.  As these investigators become independent and productive, there is an ongoing 
need for greater participation of minority investigators in the grant review process.  Like the 
community from which it is culled, study sections in general reflect the demographics of the 
scientific community, and not the communities where the research they approve will be 
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conducted.  This translation gap can be diminished by greater representation of minority 
scientists on study sections, as well as cultural awareness training of study section members. 
The increasing parallels between the domestic urban HIV epidemic and the pandemic in 
Africa and other developing nations will require a broader knowledge of the cultural impact 
of interventions to control and treat HIV infection.  These parallels have, and will continue, 
to provide research opportunities for minority investigators. 
 
Priority for Future Research: 
· Decrease the health disparities among racial and ethnic minorities to increase 
their health status to that of the majority population with respect to HIV 
infection. 
 
HIV is only one of many disease states for which significant disparities exist between racial 
and ethnic minorities and whites.  The foundation for these disparities includes, but is not 
limited to: poverty, racism, homophobia, social apathy, and a profound mistrust of the health 
care and biomedical research establishment.  This mistrust is rooted in not only historical 
lessons, such as Tuskeegee, but also in the community experience of research that has not 
left any sustainable interventions in place.  Upon completion of the trial or intervention, no 
identifiable or tangible benefit to the community has been realized.  Minority communities 
will continue to decline research participation or cooperation until there is greater 
collaboration between the community and the scientific community, with attention to the 
sustainability of the intervention before any trial is begun. 
 
Greater attention is also encouraged to the combined effects of societal factors upon the 
individual and community behavior with respect to HIV infection.  The study of racial and 
ethnic differences with respect to HIV transmission, disease progression, and resistance to 
infection is also encouraged.  The unique aspects of these communities, for example, the 
high rates of co-morbid disease states including diabetes, hepatitis C, sexually transmitted 
diseases, substance abuse and cardiovascular diseases, afford an opportunity to study 
interventions to reduce or eliminate the negative impact of these co-morbid diseases. 
 
Barriers to accessing care and clinical trials are widespread within racial and ethnic minority 
communities.  These barriers are at several levels, including individual, institutional, and 
community.  A continued emphasis on studies that identify those factors that promote and 
impede early access to care, treatment, and clinical trials is important to determine effective 
interventions.  The identification and study of these interventions to reduce or eliminate 
these barriers will be a fundamental step toward closing the gap between racial and ethnic 
minorities and whites.  However, identification alone will be insufficient, hence sustaining 
the interventions that have proven effective will be necessary to ensure ongoing attention to 
these barriers. 
 
Priority for Future Research: 
· Include racial and ethnic minorities in prevention, therapeutic, vaccine, and 
clinical trials in numbers that reflect the current incidence data. 
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Given the barriers, mistrust, and challenges noted above, intensive efforts are justified for 
the recruitment and retention of racial and minority participants in clinical trials in numbers 
that reflect the demographics of the epidemic in real time.  In order to achieve this goal, 
recruitment activities that are culturally appropriate for the specific target population will be 
necessary.  Such interventions will need to include community-based education about basic 
and clinical research, including clinical trials.  The conduct of clinical trials where 
individuals seek care and services will facilitate recruitment as well as retention. 
 
Beyond recruitment and retention are the issues that unique race and/or gender 
characteristics may have an impact upon the outcomes in transmission, side effects, body 
composition changes, and treatment side effects.  Racial and ethnic minorities must be 
recruited and retained in numbers sufficient to evaluate the presence or absence of such 
effects with adequate statistical power.  The risks and benefits of alternative and 
complementary therapies used in conjunction with standard HIV therapies require further 
study, especially in racial and ethnic minority communities, given their place in the culture. 
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Priority for Future Research: 
· Develop, pilot, evaluate, and sustain effective interventions to prevent HIV 
transmission and its co-morbidities. 
 
The risk behaviors for HIV transmission, and the means of preventing such transmission, 
have been well known for over two decades.  Yet despite this, HIV infection continues to 
spread rapidly throughout racial and ethnic minority communities.  Effective, sustainable 
prevention messages are desperately needed in these communities, as well as an 
understanding of the impact of those factors that may interfere with prevention messages. 
 
To better understand the impact of these factors, basic behavioral research is needed to 
effectively target the many sub-populations within racial and ethnic minority communities, 
including those who use illicit substances and those with multiple diagnoses (e.g., mental 
disorders and alcohol/drug abuse).  Reduction or elimination of language barriers that limit 
participation in prevention research is also needed in communities where English is not the 
primary language.  Any standardized scales to be used in these studies should have been 
validated in minority populations, especially given the cultural contexts within which risk 
behavior occurs.  The role of the family and caregivers in HIV prevention in racial and 
ethnic minority communities needs to be explored. 
 
There is a need for increased awareness of NIH HIV prevention activities at the community 
level, which can be achieved through closer collaboration between NIH and all other 
Department of Health and Human Services (DHHS) agencies charged with decreasing HIV 
transmission through public education.  Such collaborations should include, but not be 
limited to, information dissemination and translation of research findings.  These activities 
also need to include technology transfer of effective prevention programs to community-
based organizations that reach at-risk groups among racial and ethnic minorities. 
 
Priority for Future Research: 
· Promote and increase adherence to treatment regimens among racial and ethnic 
minorities. 
 
Effective drug treatment regimens identified in the controlled environment of a clinical trial 
do not perform as well in urban, inner city HIV clinics.  Poor adherence is the major reason 
for this finding and is a reflection of a host of underlying economic, individual, and social 
factors.  There is a need for the study of multilevel interventions, including the individual, 
peer, family, and community levels.  Further studies of the impact of noncompliance in 
racial and ethnic minorities upon the emergence of drug-resistant HIV, multidrug-resistant 
tuberculosis, and disease progression are needed. 
 
Increased support is recommended for basic science studies of the racial and ethnic 
differences in body composition and pharmacokinetics, and their potential role in 
suboptimal drug effects.  The impact of drug side effects and cosmetic changes and their 
role in noncompliance also warrants further study, especially in racial and ethnic minority 
communities, where such changes can unmask underlying HIV infection.  Finally, the  
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development of culturally appropriate and population-specific models of treatment 
acceptance and adherence is needed. 
 
Scientific Objectives and Strategies 
 
OBJECTIVE: 
Invest and expand funding in research infrastructure at minority institutions to 
increase capacity to support HIV/AIDS research. 
 
STRATEGIES: 
 
· Ensure adequate resources for partnership development between minority institutions 
and established university level, and federal research institutions. 
 
· Ensure information about training and recruitment opportunities is disseminated 
through a variety of traditional and non-traditional networks to reach the targeted 
population, with an ongoing evaluation of the effectiveness of these approaches. 
 
· Ensure adequate training of minority researchers in the use of the Internet and 
information resources important for research. 
 
· Ensure adequate telecommunications infrastructure at minority institutions to enable 
researchers to conduct their work. 
 
· Develop and fund HIV/AIDS research networks in minority predominant and 
minority serving institutions. 
 
· Create and fund innovative pilot sabbatical and fellowship programs to ensure 
protected research time. 
 
· Identify and fund visiting senior investigators for the purpose of enhancing the 
research capacity of minority investigators and minority institutions. 
 
· Create, support, and maintain equal partnerships between minority and majority 
researchers, as well as minority institutions. 
 
· Emphasize long-term commitments, combining investments in research and training 
as in the model AIDS International Training and Research Program (AITRP). Such 
an approach is key to long-term sustainability and success. 
 
OBJECTIVE: 
Increase the number of funded minority investigators, for greater efficacy in HIV 
research. 
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STRATEGIES: 
 
· Support the development and expansion of short and long term local and national 
mentorship programs among racial and ethnic minorities. 
 
· Identify and develop strategies to recruit trainees and mentors at all levels, while 
providing economic and in-kind support, designed to enable continued participation 
of mentors in the mentor-trainee relationship. 
 
· Increase awareness, as well as review the effectiveness of existing grant mechanisms 
and training workshops to support the transition from trainee to independent 
investigator. 
 
? Assure compliance, through the guidance given to study sections and yearly 
review of section performance, with NIH regulations for the inclusion of 
racial and ethnic minorities in research and training grants. 
 
? Create and implement cultural competency training for study section 
members, program staff, and investigators that is completed and updated on a 
biannual basis. 
 
· Provide international research opportunities for minority investigators. 
 
· Implement academic training programs that provide theoretical and practical 
framework for the conduct of clinical and basic science research for minority 
investigators. 
 
OBJECTIVE: 
Decrease health disparities among racial and ethnic minorities to increase their health 
status to that of the majority population. 
 
STRATEGIES: 
 
· Ensure that all clinical research addresses the ethical issues related to the feasibility 
of sustained access to therapeutic and prevention interventions after the research has 
concluded. 
 
· Identify and study the effectiveness of various strategies to reduce or eliminate 
health disparities at the individual, institutional and community level. 
 
? Study the effectiveness of culturally appropriate interventions for primary 
and secondary prevention. 
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? Study the factors that promote and impede early access to care, treatment, 
and interventions. 
 
· Study the combined effects of several factors, including but not limited to: poverty, 
racism, homophobia, and homelessness in creating the health disparities observed 
within racial/ethnic minorities (at the individual and community level). 
 
? Study the combined effects of societal factors on the individual and 
community behavior, with respect to HIV infection. 
 
? Study the biology of HIV infection among racial and ethnic minorities 
including vulnerability to HIV and opportunistic infections, transmission, 
disease progression, and resistance. 
 
· Encourage and fund basic and clinical research to understand the influence of 
cultural, economic, biological, behavioral, gender, and age factors upon racial and 
ethnic minority health disparities in HIV/AIDS. 
 
· Study the impact of other co-morbid diseases and management of symptoms 
including, but not limited to, tuberculosis, hepatitis B and C, mental illness, diabetes, 
substance abuse, and sexually transmitted diseases on health outcomes and access to 
care. 
 
? Study interventions to reduce or eliminate the negative impact of these co-
morbid diseases. 
 
? Study the cost-effectiveness and replicability of the interventions. 
 
· Study the differential responses to HIV and opportunistic infection therapy, 
including side effects among racial and ethnic minorities. 
 
OBJECTIVE: 
Include racial/ethnic minorities in prevention, therapeutic, vaccine and clinical trials in 
numbers that reflect the current incidence data. 
 
STRATEGIES: 
 
· Develop and fund recruitment activities that are culturally appropriate for the 
specific target population. 
 
? Provide community-based education about basic and clinical research, 
including clinical trials. 
 
? Conduct clinical trials where individuals seek medical care and services. 
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? Develop partnerships between NIH-funded research institutions and 
institutions in the targeted communities, including community-based 
organizations. Research infrastructure development within these community 
partners is an essential component of this partnership. 
 
? Include community input from the initiation of study development to the 
dissemination of study results. 
 
· Increase the emphasis upon study design and methods when planning and conducting 
studies that will better determine the impact of racial/ethnic/gender differences upon 
outcomes in transmission, side effects, body composition (e.g., pathogenesis, drug 
treatment, and clades). 
 
· Conduct studies of the risks and benefits of complementary and alternative therapies 
that may be used in conjunction with standard HIV therapies. 
 
· Encourage the use of ClinicalTrials.gov and the AIDS Clinical Trials Information 
Service as a tool to inform and promote and understanding of the clinical trials 
process, and current clinical trials in minority populations. 
 
OBJECTIVE: 
Develop, pilot, evaluate, and sustain prevention interventions to prevent HIV 
transmission and its co-morbidities. 
 
STRATEGIES: 
 
· Increase research to identify the specific mechanisms of transmission, and the critical 
factors that influence transmission, among racial/ethnic minorities. 
 
? Identify the significant factors (e.g., stigma, poverty, racism, sexism, 
violence, and homophobia) that interfere with prevention messages. 
 
? Fund research conducted with the multiply diagnosed HIV/AIDS infected 
population (e.g., mental disorders, alcohol/substance abuse, and medical 
disorders). 
 
? Develop and support innovative models to conduct outcome evaluations in 
racial/ethnic minority communities. 
 
? Ensure that any standardized scales to be used in studies that include racial 
and ethnic minorities have been validated in minority populations. 
 
? Increase community-level awareness of HIV prevention through closer 
collaborations between NIH and all other Department of Health and Human 
Services (DHHS) agencies charged with decreasing HIV transmission 
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through public education. Such collaboration should include, but not be 
limited to, information dissemination and translation of research findings. 
 
? Reduce or eliminate language barriers which limit participation in prevention 
research in communities where English is not the primary language. 
 
· Study the effect of nutrition and micronutrients on the impact of HIV and 
opportunistic infection therapies and their side effects. 
 
· Support technology transfer of prevention programs to communities that reach at-
risk groups among racial and ethnic minorities. 
 
· Support research on the role of family and caregivers in prevention in minority 
communities. 
 
OBJECTIVE: 
Promote and increase adherence to treatment regimens among racial and ethnic 
minorities. 
 
STRATEGIES: 
 
· Increase support for basic science studies of metabolic, body composition and 
pharmacokinetic racial and ethnic differences and their potential role in sub-optimal 
drug effects. 
 
· Study the short- and long-term effects of noncompliance in racial and ethnic 
minorities, including but not limited to, the emergence of drug-resistant HIV, 
multidrug resistant tuberculosis [MDR-TB], opportunistic infections [OIs]), and 
disease progression. 
 
· Study the effects of multilevel interventions (individual, peer, family, community) on 
adherence. 
 
· Study racial and ethnic differences in adherence, and the gender-related issues and 
gender differences associated with the chronic noncompliance. 
 
· Study new therapeutic regimens that would facilitate adherence. 
 
· Develop culturally appropriate and population-specific models of treatment 
acceptance and adherence. 
 
· Study of the impact of minor and severe side effects on adherence (e.g., the impact 
of cosmetic changes associated with antiretroviral therapy). 
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